|1.||Küntscher, Markus V: 3 articles (04/2007 - 01/2002)|
|2.||Germann, Günter: 3 articles (04/2007 - 01/2002)|
|3.||Zhu, Xiaoping: 2 articles (02/2003 - 01/2003)|
|4.||Menke, Henrik: 2 articles (01/2003 - 01/2002)|
|5.||Gebhard, Martha Maria: 2 articles (01/2003 - 01/2002)|
|6.||Altmann, Jens: 2 articles (01/2003 - 01/2002)|
|7.||Büyüknacar, Hacer Sinem: 1 article (01/2014)|
|8.||Seçilmiş, Mehmet Ata: 1 article (01/2014)|
|9.||Göçmen, Cemil: 1 article (01/2014)|
|10.||Ertuğ, Fatma Peyman: 1 article (01/2014)|
06/01/1997 - "5. These results suggest that locally administered spermine-NONOate is effective in slowing the development of neointima in this model."
06/01/1997 - "4. After 14 days with collars, treatment with spermine-NONOate had significantly reduced (by 74%) the thickness of the neointima in comparison with the contralateral collared artery without compound. "
06/01/1997 - "A nitric oxide donor (spermine-NONOate) prevents the formation of neointima in rabbit carotid artery."
07/01/2002 - "Our data show that pharmacological preconditioning and enhancement of flap survival can be achieved by intravenous administration of Sper/NO. The application of Sper/NO at the end of the ischaemia period or in the early reperfusion period provides no protection against ischaemia-reperfusion injury."
01/01/2008 - "In the present study, the roles of the NO donor spermine NONOate and tumour necrosis factor-alpha (TNF; as a positive control) in prostaglandin production and angiogenic activity of equine endometria during the oestrous cycle were evaluated. "
04/01/2007 - "The application of similar doses into the flap artery resulted in 63.5%, 72.3%, and 64.3% flap necrosis; 52.7% average flap loss was observed in an additional group receiving Sper/NO adjusted to flap weight (500 nmol/kg flap weight). "
07/01/2002 - "The group receiving Sper/NO just prior to reperfusion demonstrated a significantly higher mean area of flap necrosis than the non-ischaemic controls (P < 0.05), but did not differ significantly from the control group. "
07/01/2002 - "The group with pre-ischaemic application of Sper/NO showed a significantly lower area of flap necrosis than either of the control groups or the group receiving Sper/NO just prior to reperfusion (P < 0.05). "
07/01/2002 - "The group with pre-ischaemic application of Sper/NO demonstrated an average flap necrosis of mean+/-s.d. "
|4.||Atherosclerotic Plaque (Atheroma)
02/01/2003 - "Spermine NONOate did not alter isotonic contractile and fatigue properties during hypoxia. "
09/16/2008 - "Additionally, NO donor spermine NONOate could inhibit the AChE activity in brain homogenates in a concentration-dependent manner, which further substantiate that nitric oxide produced during post hypoxia re-oxygenation, primarily contributes to the observed inhibition of cortical AChE activity. "
10/01/2002 - "ROS levels and leukocyte adherence in mesenteric venules of rats during hypoxia were studied in the absence and presence of an NO donor [spermine NONOate (SNO)] and of the NO precursor L-arginine. "
01/01/2000 - "Hypoxia-induced c-fos mRNA expression, and promoter activities were significantly potentiated in presence of spermine nitric oxide (SNO), a NO donor. "
11/15/2005 - "Isogenic HCT116 and HCT116 TP53-/- colon cancer cells were exposed to the NO* donor Sper/NO, H2O2, hypoxia, or hydroxyurea, and their mRNA was analyzed using oligonucleotide microarrays. "
|1.||Nitric Oxide (Nitrogen Monoxide)
|4.||spermine nitric oxide complex
|6.||Peroxynitrous Acid (Peroxynitrite)
|7.||Messenger RNA (mRNA)
|8.||omega-N-Methylarginine (NG Monomethyl L Arginine)